Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Single-Cell Transcriptome Integration Analysis Reveals the Correlation Between Mesenchymal Stromal Cells and Fibroblasts.

Fan C., Liao M., Xie L., Huang L., Lv S., Cai S.

Laboratory Study on Immune Modulation, published in Front Genet (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Genet (2022)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
35360851
DOI
10.3389/fgene.2022.798331

Abstract (original English)

Background: Mesenchymal stromal cells (MSCs) and fibroblasts show similar morphology, surface marker expression, and proliferation, differentiation, and immunomodulatory capacities. These similarities not only blur their cell identities but also limit their application. Methods: We performed single-cell transcriptome sequencing of the human umbilical cord and foreskin MSCs (HuMSCs and FSMSCs) and extracted the single-cell transcriptome data of the bone marrow and adipose MSCs (BMSCs and ADMSCs) from the Gene Expression Omnibus (GEO) database. Then, we performed quality control, batch effect correction, integration, and clustering analysis of the integrated single-cell transcriptome data from the HuMSCs, FMSCs, BMSCs, and ADMSCs. The cell subsets were annotated based on the surface marker phenotypes for the MSCs ( CD105 + , CD90 + , CD73 + , CD45 - , CD34 - , CD19 - , HLA-DRA - , and CD11b - ), fibroblasts ( VIM + , PECAM1 - , CD34 - , CD45 - , EPCAM - , and MYH11 - ), and pericytes ( CD146 + , PDGFRB + , PECAM1 - , CD34 - , and CD45 - ). The expression levels of common fibroblast markers ( ACTA2 , FAP , PDGFRA , PDGFRB , S100A4 , FN1 , COL1A1 , POSTN , DCN , COL1A2 , FBLN2 , COL1A2 , DES , and CDH11 ) were also analyzed in all cell subsets. Finally, the gene expression profiles, differentiation status, and the enrichment status of various gene sets and regulons were compared be

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research